Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week,open label,randomized controlled study in Japan (PREFERENCE 4 study)
1. Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan;2. Department of Endocrinology, Tenri Hospital, Tenri, Nara, Japan;3. Department of Diabetes Medicine, Nara City Hospital, Nara, Japan